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Abstract
Background: A critical step in the production of new HIV virions involves the TAT protein
binding to the TAR element. The TAT protein contains in close proximity its TAR RNA binding
domain and protein transduction domain (PTD). The PTD domain of TAT has been identified as
being instrumental in the protein's ability to cross mammalian cell and nuclear membranes. All
together, this information led us to form the hypothesis that a protein containing the TAR RNA
binding domain could compete with the native full length TAT protein and effectively block the TAR
RNA binding site in transduced HIV infected cells.
Results: We synthesized a short peptide named Tat-P, which contained the TAR RNA binding and
PTD domains to examine whether the peptide has the potential of inhibiting TAT dependent HIV
replication. We investigated the inhibiting effects of Tat-P in vitro using a HIV derived lentiviral
vector model. We found that the TAT PTD domain not only efficiently transduced test cells, but
also effectively inhibited the production of lentiviral particles in a TAT dependent manner. These
results were also supported by data derived from the TAT activated LTR-luciferase expression
model and RNA binding assays.
Conclusion: Tat-P may become part of a category of anti-HIV drugs that competes with full length
TAT proteins to inhibit HIV replication. In addition, this study indicates that the HIV derived
lentiviral vector system is a safe and reliable screening method for anti-HIV drugs, especially for
those targeting the interaction of TAT and TAR RNAs.
Background
The HIV TAT protein is a key regulator of viral replication
[1]. Binding of the TAT protein to the TAR element, a 59
nt sequence at the 5' end of nascent RNA, is the first criti-
cal step for producing full length HIV RNA. The transcrip-
tion of HIV RNA from both integrated and non-integrated
HIV genome is dependent on TAT protein [2]. Thus, inter-
ruption of this TAT-TAR interaction has been considered
as a possible way to inhibit HIV replication [3]. TAR RNA
decoys have been shown to be able to interfere with the
binding of TAT proteins to native TAR elements, thus
inhibiting HIV replication [4-6]. However, delivery of oli-
gonucleotides in vivo is not trivial. Conversely, small syn-
thetic substances, or short TAT peptides mimicking the
TAT and TAR RNA binding domains have been shown to
be promising inhibitors of HIV replication [7,8]. Further-
more, a different fragment of the TAT protein could com-
pete for the binding site of the CXCR4 receptor on T cells
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and inhibit HIV entry [9]. Recently, several research
groups have identified the TAR RNA binding domain of
the TAT protein to be an arginine rich region (aa 49–59)
[10,11]. In addition, TAT has been found to contain a pro-
tein transduction domain (PTD) that is able to cross cell
membranes to freely enter cells [12]. Furthermore, this
TAT PTD also has the ability to deliver big and small mol-
ecules into target cells and cell nuclei [13-15]. We have
found that the TAT PTD and the TAR RNA binding
domain are located in the same region of the TAT protein.
The close proximity of these two properties led us to
hypothesize that the sequence of this region could serve as
a decoy by competing with full-length native TAT pro-
teins. Blocking the interaction between native TAT pro-
teins and the TAR RNA could subsequently inhibit viral
replication.
The lack of access to hazardous HIV laboratories has hin-
dered anti-HIV drug development. For this reason, it is
important to explore substitute HIV models. One option
is to use non-human lentiviral models, such as equine
infectious anemia virus (EIAV) [16], feline immunodefi-
ciency virus (FIV) [17], bovine immunodeficiency virus
(BIV) [18], and simian immunodeficiency virus (SIV)
[19,20]. While these animal models have revealed impor-
tant lentivirus replication and pathogenesis mechanisms,
some discrepancies still exist between animal and human
lentiviruses (HIV). For instance, the above animal models
may not reflect the actual HIV life cycle in humans.
A different research method is represented by the HIV
derived recombinant lentiviral vector system, which was
developed for human gene therapy purposes [21]. First
Transduction of 293T cells by Tat-P and Con-P1 Figure 1
Transduction of 293T cells by Tat-P and Con-P1. To test the capability of Tat-P to cross 293T cell membranes, FITC 
labeled Tat-P, Con-P1 or Con-P2 peptides were added to 293T cells with concentrations ranged from 6.25 µM and 200 µM. 
Three hours later, cells were washed extensively with PBS and viewed under fluorescent microscope (Magnification ×200) 
(Panel A). In some experiments, after transduction with 200 µM peptides, 293T cells were fixed and the nuclei were counter-
stained with Sytox Orange (red). Cells were then visualized under confocal microscope (Magnification ×1000) (Panel B).Retrovirology 2005, 2:71 http://www.retrovirology.com/content/2/1/71
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Inhibition of recombinant lentiviral vector generation by Tat-P peptide Figure 2
Inhibition of recombinant lentiviral vector generation by Tat-P peptide. Panel A. To visualize the genetically gener-
ated pseudo HIV particles, 293T cells were co-transfected for 24 hours with 3 plasmids: pCMV ∆8.91, pMD VSV-G, and 
pHR'GFP. Then 200 µM of Tat-P and Con-P1 peptides, and the same amount of PBS, were added to the 293T cells for 12 
hours. The cells were then fixed and sectioned for EM imaging (Magnification × 60,000). Arrows indicate the virus particles. 
Panel B and Panel C. To examine the Tat-P inhibition of HIV derived recombinant lentiviral vectors, 293T cells were cotrans-
fected with 3 plasmids for 24 hours. The medium was replaced with DMEM containing 200 µM of Tat-P, Con-P1, Con-P2 pep-
tides or PBS. Six hours later, the supernatants containing the viral particles were collected and the vector titers were 
determined. A representative from three individual experiments is presented. Panel D. Percent inhibition was calculated using 
the formula (1-titer in the presence of peptide/titer in the presence of PBS) × 100.Retrovirology 2005, 2:71 http://www.retrovirology.com/content/2/1/71
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generation HIV based lentiviral vectors were generated by
deleting the viral envelope gene (env) and replacing it
with the vesicular stomatitis virus glycoprotein (VSV-G)
gene to eliminate viral tropism for T lymphocytes and
macrophages. In addition, gag, pol, and other regulatory
HIV proteins were encoded on separate plasmids that
were then co-transfected into the target cells. To improve
on safety in second generation viral vectors, the accessory
proteins encoding the nef, vif, vpu, and vpr genes were
further deleted to reduce chances of generating replication
competent recombinants [22]. However, the TAT and REV
proteins were still required for producing lentiviral vectors
and were provided by separate plasmids. In third genera-
tion lentiviral vectors, the introduction of strong chimeric
promoters drove the full length RNA without the assist-
ance of TAT [23]. Because second generation lentiviral
vectors are dependent on TAT, we should be able to design
experiments to examine anti-HIV approaches that target
the TAT protein. Simultaneously, the third generation len-
tiviral vectors that are TAT independent can be used as
controls. As described above, the use of theses vectors rep-
resent a strong biosafety profile. Additionally, by coding a
marker gene into the recombinant lentiviral vector model,
such as green fluorescent protein (GFP), we can easily
measure viral infectivity and titer through cell counts,
rather than measuring viral load indirectly through p24 or
other viral structural products.
In this study, we describe the synthesis of a short peptide
named Tat-P, which shares the same sequence as the TAR-
RNA binding domain and the TAT PTD domain, and this
peptide was evaluated in vitro using the HIV derived
recombinant lentiviral vector model to examine its poten-
tial for inhibiting TAT dependent HIV replication. The
ultimate goal of these studies was to determine if Tat-P
could cross cellular and nuclear membranes and effec-
tively block native TAT proteins from binding to TAR-
RNA.
Results
Tat-P and Con-P1 peptides efficiently transduced 293T 
cells
In order to prevent native TAT proteins from binding to
TAR-RNA, Tat-P must have the capability of crossing cell
and nuclear membranes. To assess the transduction effi-
ciency of Tat-P and two control peptides, Con-P1 and
Con-P2, we synthesized FITC conjugated peptides. Con-
P1 was utilized as a positive control because previous
studies have demonstrated that this peptide shares similar
structure and cell entry properties to Tat-P, conversely,
Con-P2 represented a negative control because it lacks the
PTD domain and its associative cell entry capabilities [24].
The 293T cells were treated with FITC labeled peptides
ranged from 6.25 µM to 200 µM for 3 hours at 37°C, and
internalization of these peptides was evaluated by fluores-
cent microscopy. As shown in Fig. 1A, the 293T cells dis-
played high levels of transduction by both Tat-P and Con-
P1, and that the degree of transduction for these peptides
was observed to be dose dependent. Furthermore, the
peptide was found in the nucleus of transduced cells when
examined with confocal microscopy (Fig. 1B), suggesting
that the peptide was indeed inside the cells not simply
attached to the cell surface. As expected, the Con-P2 neg-
ative control peptide was unable to transduce the 293T
cells. These data confirm previous reports that Tat-P can
cross cell membranes to enter the cytoplasm and then the
nucleus.
Tat-P inhibited the viral production of second-generation 
recombinant lentiviral vector
To evaluate the blocking of HIV TAT and TAR RNA inter-
action as a feasible target for anti-HIV drug development
and to test whether the Tat-P blocks lentiviral vector parti-
cles production, 293T cells were transfected with three
plasmids providing necessary genes to package replica-
tion-defective pseudo-typed HIV particles. Twenty-four
hours after the transfection, Tat-P or the control peptides
Con-P1 and Con-P2, were added to the cells. If Tat-P is
able to compete with full length TAT protein for binding
to TAR-RNA, it should block TAT transactivation activity
and thus inhibit the viral RNA transcription and lentiviral
production. We utilized the following two indicators to
evaluate the inhibition of recombinant lentiviral produc-
tion.
(1) Visualization of HIV production by electronic microscopy (EM)
Twenty-four hours following transfection, the media was
replaced with fresh media containing 200 µM of Tat-P,
Con-P1, or the same amount of PBS for 12 hours. The
cells were then fixed and sectioned for transmission EM
imaging. Fig. 2A shows that HIV particles were formed by
the Tat-P and Con-P1 transfected 293T cells. From these
EM images, the recombinant lentiviral vectors were visu-
alized as 80~100 nm enveloped viral particles. It is impor-
tant to note that the Tat-P treated cells showed formation
of fewer viral particles than those of Con-P1 and the PBS
treated controls.
(2). Reduction in lentiviral titers following addition of the Tat-P
To accurately assess the Tat-P inhibition capability, we
measured the lentiviral vector titer in the cell culture
supernatant generated from co-transfection in the pres-
ence or absence of peptides. As shown in Fig. 2B, cell cul-
ture supernatant from co-transfection in the presence of
Tat-P generated significantly fewer number of GFP posi-
tive cells, indicating much lower lentiviral vector titer in
the preparation. The vector titer was calculated based on
the initial number of 293T cells when lentiviral vector was
added. The lentiviral vector titer was dramatically reduced
in the presence of Tat-P (Fig. 2C). The inhibition effects ofRetrovirology 2005, 2:71 http://www.retrovirology.com/content/2/1/71
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Tat-P, Con-P1, and Con-P2 on the lentiviral production
were calculated to be 89.8%, 4%, and 5.9% compared to
PBS control, respectively (Fig. 2D), suggesting that Tat-P
strongly inhibit the lentiviral production in the setting of
three plasmids co-transfection approach.
Tat-P inhibition of virus production was constant over time 
and the degree of inhibition was dose dependent
Tat-P inhibition effect was also demonstrated in the time
point of 12 hours and 24 hours after addition of the pep-
tide. As shown in Fig. 3A, the inhibition rates were 83%
and 79%, respectively. The inhibition effect was decreased
with incremental time length possibly due to the peptide
degradation. In contrast, Con-P1 peptide had no inhibi-
tion effect at all time points, further suggesting the inhibi-
tion by Tat-P was specific. To evaluate the dose-response
effect of the Tat-P on viral production, three different
doses of Tat-P (200 µM, 100 µM and 50 µM) were utilized
in the experiment. At each dose of the treatment, Tat-P
inhibited the viral production quantified by flow cytome-
try (Fig. 3B) when compared to Con-P1 treatment and
PBS control (data not shown). Compared to Con-P1 pep-
tide, the inhibition rates of Tat-P were calculated to be
87.1% at 200 µM, 72.7% at 100 µM, and 59.2% at 50 µM.
Tat-P did not inhibit third generation virus production
In this experiment, we evaluated whether the inhibition of
HIV replication by Tat-P was TAT protein dependent.
Since the TAT protein is not required to produce third gen-
eration recombinant lentiviral vectors, then Tat-P should
not inhibit third generation viral production. 293T cells
were co-transfected within a third generation (TAT inde-
pendent) lentiviral vector system. After exposure to Tat-P,
Con-P1, Con-P2 and PBS, the cell supernatants were
measured to determine virus titers (Fig. 4). All three pep-
tides showed low levels (<10%) of virus replication inhi-
bition. These data strongly support that the Tat-P
inhibition of virus replication present above was occur-
ring through direct interference with the native TAT pro-
teins and their target TAR-RNA.
Tat-P toxicity of 293T cells did not occur at concentrations 
less than 400 µM
To evaluate the cell toxicity of Tat-P, escalating doses of
the peptides were applied to 293 T cells. The cell viability
was measured using MTT assay. Fig. 5 showed that the
addition of Tat-P to the cell culture medium did not affect
293T cell viability up to 200 µM. A low level of toxicity
was observed when the peptide concentration reached
400 µM. However, this toxicity level was similar to that
induced by control peptides Con-P1 and Con-P2, suggest-
ing that the inhibition of recombinant lentiviral produc-
tion Tat-P is not due to the effect of cell toxicity.
Tat-P Inhibits TAT Activated LTR-Luciferase Activity
To verify the results that Tat-P competitively inhibited HIV
based lentiviral production via interference with TAR RNA
binding, HIV LTR-luciferase expression model was estab-
lished by cotransfection of 293T cells with pLTR-luc and
pCMV-TAT plasmids. The expression of luciferase is aug-
mented in the presence of full length TAT protein through
the binding of TAR RNA. The binding of Tat-P to TAR RNA
should competitively block the interaction of TAT protein
with TAR RNA, resulting in reduction of reporter gene
expression. As demonstrated in Fig. 6A, luciferase activity
decreased in the presence of Tat-P in a dose dependent
manner. In contrast, Con-P1 peptide has no effect of luci-
ferase gene expression, suggesting that the inhibitory
effect of Tat-P ensues from competition with TAT protein
Time and dose effects of Tat-P on recombinant lentiviral vec- tor production Figure 3
Time and dose effects of Tat-P on recombinant lenti-
viral vector production. Panel A. To investigate the Tat-P 
driven inhibition of lentiviral vector generation over time, 
supernatants from the viral particle producing 293T cell cul-
tures, in the presence of 200 µM of Tat-P, Con-P1, Con-P2, 
and PBS, were collected at 6 hour, 12 hour, and 24 hour time 
points. The supernatants containing the viral particles were 
added to freshly cultured 293T cell and these supernatants 
were evaluated for virus titers. Panel B. To assess dose-
dependency of the Tat-P inhibition activity, supernatants 
from the viral particle producing 293T cell cultures, in the 
presence of 200 µM, 100 µM, and 50 µM of Tat-P and Con-
P1, were collected at the 6-hour time point. Viral titers were 
determined and the inhibition effects were calculated.Retrovirology 2005, 2:71 http://www.retrovirology.com/content/2/1/71
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and does not represent nonspecific transcription inhibi-
tory effect.
Tat-P Specifically Binds To TAR-RNA
We next investigated whether Tat-P's antiviral activity was
due to specific binding to TAR-RNA by performing Tat-P
and TAR-RNA binding assays in vitro. Tat-TAR-RNA com-
plexes were formed by mixing serial dilutions of Tat-P
peptide with TAR-RNA, and resolving the peptide-RNA
complexes by electrophoresis on polyacrylamide gels. Fig.
6B shows that Tat-P peptides did bind to the TAR-RNA
and these complexes are represented by upward shifts in
the gel. As the concentration of Tat-P increased (left to
right), the RNA bands showed a continuous step-up pat-
tern indicating increasing density. No such phenomenon
was observed for the control peptides, suggesting that the
Tat-P peptides were binding specifically to the TAR-RNA.
Discussion
Currently, treatments for HIV infection rely heavily on
anti-viral therapies. Most of these therapies target the HIV
reverse transcriptase and protease enzymes by using nucl-
eoside analogues as enzymes inhibitors, and their combi-
nation, known as highly active antiretroviral therapy
(HAART), has markedly decreased mortality and morbid-
ity in the developed world. The disadvantages of HAART
include its inability to completely eradicate HIV from the
body, long-term toxicity, and eventually the emergence of
drug-resistant HIV strains [25]. Furthermore, the majority
of HIV carriers have limited access to anti-retrovirals
(ARVs) because of high costs and problems with patient
compliance. It is, therefore, vital to find new strategies for
identifying anti-HIV remedies, such as new targets of viral
replication, new sources of drugs, and safe anti-HIV drug
screening models.
Interruption of the formation of TAT-TAR-RNA complex
represents such an endeavor. Small molecules mimicking
either the native TAT peptides or TAR-RNA decoys have
been investigated as new approaches for inhibiting HIV
replication [4-9]. The lack of access to hazardous HIV lab-
oratories is one of major hurdles for developing anti-HIV
drugs. One option to overcome this restriction is to
develop lower-risk assays for use in BSL-2 laboratories.
Recombinant lentiviral vectors, widely used for gene ther-
apy research could offer a potential substitute model for
evaluating the efficacy of anti-HIV drugs. This may espe-
cially be true for candidate drugs targeting the interaction
between TAT and TAR-RNA, the interaction of which is
required for producing second generation recombinant
lentiviral vectors. Based on the observation that the short
Tat-P peptide can freely enter cells and specifically bind to
TAR-RNA, we investigated the hypothesis that HIV repli-
cation could be inhibited by Tat-P peptides blocking
native TAT proteins from binding to the TAR-RNA, and
that these studies could be performed using HIV derived
lentiviral model.
In these studies, we found that Tat-P was able to transduce
293T cell membranes without significant toxicity, and
that the peptides inhibited recombinant lentiviral produc-
tion in a TAT dependent manner. The inhibition of
recombinant lentiviral production by Tat-P likely resulted
from the competitive binding with TAR-RNA and the
blocking of full length TAT by Tat-P. As demonstrated in
Fig. 6B, Tat-P could bind to TAR RNA. More importantly,
luciferase gene expression from TAT responsive LTR pro-
moter was inhibited by the presence of Tat-P (Fig. 6A),
further suggesting that the inhibition effect of Tat-P is
mediated by interference with TAT-TAR RNA interaction.
Compared to the dramatic inhibition of infective lentivi-
ral particles (Fig. 3), the inhibition of luciferase gene
expression from TAT responsive promoter by Tat-P seems
less dramatic (Fig. 6A). Such discrepancy was also
observed previously by others using TAT responsive pro-
moter driven CAT assay (7). One possible explanation for
the difference is that there is a higher amount of TAT pro-
tein may be produced from co-transfected plasmid pCMV-
TAT. Thus, the same amount of Tat-P result in less effective
No inhibition of third generation lentiviral vectors by Tat-P  was observed Figure 4
No inhibition of third generation lentiviral vectors by 
Tat-P was observed. To test that the Tat-P inhibition 
activity is specifically targeting HIV TAT protein, 293T cells 
were cotransfected with four plasmids of a third generation 
lentiviral vector system that is independent of the TAT pro-
tein. Then, 200 µM of Tat-P, Con-P1, and Con-P2 peptides, 
or a PBS control were added to the 293T cells for 6 hours. 
The supernatants containing the viral particles were col-
lected and added to freshly cultured 293T cells to measure 
viral titers.Retrovirology 2005, 2:71 http://www.retrovirology.com/content/2/1/71
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competitive inhibition. In contrast, TAT protein level in
the generation of viral particles by co-trasnfection method
may be lower since it is generated by polycistronic mRNA
from plasmid pCMV ∆8.91. Alternatively, viral particle
production is a multiple steps process dependent on TAT.
The competitive inhibition of TAT function by Tat-P may
be amplified in the subsequent steps, resulting in more
dramatic reduction of infective viral particles. In addition,
it is possible that production of longer RNA is more
dependent on the action of TAT, whereas the shorter luci-
ferase gene expression from LTR promoter may be less
dependent on TAT. Therefore, competitive blocking of
TAT interaction with TAR RNA by Tat-P results in less dra-
matic inhibition of luciferase activity.
The recombinant lentiviral vector model has two advan-
tages over natural HIV cell culture model. First, it is safer
and able to be conducted in most laboratories. Second, it
is an alternative approach for evaluating the infective
recombinant viral particles. However, it is not clear if this
recombinant lentiviral vector system can also be used to
screen other anti-HIV drugs, such as those that target
reverse transcriptase and proteinase. The split of one HIV
genome into three different plasmids in generating a len-
tiviral vector may create an artificial setting for studying
viral pathogenesis, which may affect the anti-HIV mecha-
nisms. Thus, the results obtained through this recom-
binant lentiviral vector system need to be validated by
conventional in vitro cell culture screening methods. Nev-
ertheless, our research has shown that the recombinant
lentiviral vector in vitro generation model may provide an
easy and safer assay for primary screenings of ARV drugs
before moving on to more involved methods requiring
restricted P3 facilities.
Conclusion
Based on the above results, we draw the following conclu-
sions: Tat-P inhibits HIV derived lentiviral production by
blocking native TAT proteins from binding to TAR-RNA;
genetically generated HIV models can be applied to screen
anti-HIV drugs before using the high risk wild type HIV
models; the results obtained from a recombinant lentivi-
ral vector in vitro model need to be validated using wild
type HIV cell culture methods and animal models.
Cytotoxicity of Tat-P on 293T cells Figure 5
Cytotoxicity of Tat-P on 293T cells. To test for peptide toxicity, Tat-P, Con-P1, and Con-P2 peptides in concentrations 
ranging from 0 µM to 400 µM were added to 293T cells at 37°C for 6 hours, and the cell viabilities were monitored by MTT 
assay.Retrovirology 2005, 2:71 http://www.retrovirology.com/content/2/1/71
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Methods
Peptides and RNA
Tat-P (47YGRKKRRQRRR57) [10,12], Con-P1 (RRQRRT-
SKLMKR) [24] that shares similar structure and transduc-
tion efficiency as Tat-P, and Con-P2 (ARPLEHGSDKAT)
[24] that lacks the capability of cell transduction, were
synthesized (Peptide Synthesis Facility, University of Pitts-
burgh) using standard fmoc chemistry, then cleaved and
deprotected by stirring in a 95% TFA, 2.5% triisopropylsi-
lane, 2.5% H2O solution. The peptides were purified by
reverse phase high performance liquid chromatography to
>90% purity. Lyophilized peptides were reconstituted in
PBS before use. To generate FITC labeled peptides, the flu-
orescein moiety (Fl) was attached via an aminohexanoic
Inhibitory effect of Tat-P on TAT activated LTR-Luciferase activity and specific TAR RNA binding by Tat-P Figure 6
Inhibitory effect of Tat-P on TAT activated LTR-Luciferase activity and specific TAR RNA binding by Tat-P. 
Panel A. The TAT activated LTR-luciferase assay: 239T cells were co-transfected with the pLTR-luc and pCMV-TAT plasmids, 
and Tat-P and Con-P1 peptides (200 µM, 100 µM, 50 µM) were added to the cells 6 hours after transfection. The conditioned 
media were exchanged with fresh media containing the same amounts of peptides after 12 hours. The cells were harvested 6 
hours later and processed by luciferase assay. The inhibition rates were expressed as mean ± SE. Panel B. The RNA binding 
assay: 0.25 nmol of TAR RNA was incubated with Tat-P or control peptides (Con-P1 and Con-P2) at indicated Peptide: TAR 
RNA molar ratio in a total 10 ul of reaction mixture for 15 minutes on ice. Free RNAs and peptide-RNA complexes were 
resolved by electrophoresis at 25°C on 15% polyacrylamide gels, and imaged using a fluorescent-based EMSA kit.Retrovirology 2005, 2:71 http://www.retrovirology.com/content/2/1/71
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acid spacer by treating a resin-bound peptide (1.0 mmol)
with FITC (1.0 mmol) and diisopropyl ethyl amine (5
mmol) in dimethylformamide (DMF; 10 ml) for 12 h
[26]. Cleavage from the resin was achieved by using 95:5
trifluoroacetic acid (TFA)/triisopropylsilane. Removal of
the solvent in vacuo gave a crude oil that was triturated
with cold ether. The crude mixture thus obtained was cen-
trifuged, the ether was removed by decantation, and the
resulting orange solid was purified by RP-HPLC (H 2O/
CH3CN in 0.1% TFA). The TAR RNA 29mer 5'-GCCA-
GAUCUGAGCCUGGGAGCUCUCUGGC-3' [10] was
purchased from Dharmacon (Lafayette, CO) and the RNA
was purified with PAGE gel and desalted by the manufac-
turer.
Transduction of 293T cells by peptides
FITC labeled Tat-P, Con-P1, and Con-P2 peptides were
added to 293T cells at concentrations ranged from 6.25
µM to 200 µM and incubated at 37°C for 3 hours. The
cells were washed extensively with PBS (pH.7.2) to
remove excess peptides. Transduction of cells was visual-
ized under a fluorescent microscope. To determine if the
peptides were actually inside the cells, we conducted con-
focal microscopy study by co-staining the transduced cells
with nucleus staining. 293T cells were transduced with
200 µM peptides. Three hours later, the treated cells were
washed with tris buffered saline (TBS, pH 7.4) and fixed
with 2% of paraformaldehyde containing 0.1% of Triton
X-100 (Sigma, St. Louis, MO). The nuclei were stained
with 1:2000 of Sytox Orange (Molecular Probes, Eugene,
OR) and the peptide intracellular uptake was examined by
confocal microscopy.
In vitro generation of lentiviral vectors
The production of second and third generation recom-
binant lentiviral vectors was performed as described pre-
viously using a three- or four- plasmids cotransfection
procedure [22,27]. For generating third-generation lenti-
viral vectors, 80% confluent 293T cells were transfected
with plasmid DNA pLenti-EGFP-TRIP together with pack-
aging plasmids, pLP1, pLP2, and pVSV-G, (Invitrogen,
San Diego, CA) using the calcium phosphate precipitation
method according to manufacturer's description (Strata-
gene, San Diego, CA). To produce second-generation VSV
pseudo-typed lentiviral vectors, plasmid pCMV ∆8.91
expressing the core proteins and enzymes of HIV, plasmid
pMD VSV-G providing the envelope protein of VSV-G,
and plasmid pHR'GFP expressing the green fluorescence
protein (GFP) were utilized to transfect 293T cells using
the same method as above. Handling of viral vectors was
according to the guideline of BSL-2+ laboratories estab-
lished by the Recombinant DNA Committee of University
of Pittsburgh.
Assays for Tat-P inhibition of HIV lentiviral production
Twenty-four hours after the three plasmid transfection,
media were replaced with fresh media containing differ-
ent concentrations of the peptides. Cell supernatants con-
taining viral particles were collected at 6 hour, 12 hour,
and 24 hour time points to determine the viral titers by
transducing 293T cells. Media collected at different time
points were diluted two fold with fresh media containing
8 µg/ml of polybrene and then added to 293T cells. Two
days later, cells were collected and the transduced EGFP+
cells were analyzed using flow cytometry (BD Bioscience,
CA). Percentage of transduction was calculated. The quan-
titative data collected were expressed as mean ± SD, and
the viral inhibition rates were calculated by the formula:
Inhibition rate = (1 - Number of Tat-P Treated Green
Cells/Number of Green Cells of a Control) × 100%.
Visualization of viral particles using electronic microscope
Twenty-four hours after transfection, Tat-P, Con-P1, or
PBS was added to the 293T cells for 12 hours. The cells
were washed with PBS twice and fixed using 2% glutaral-
dehyde. Viral particles were examined by electronic micro-
scope (EM) imaging.
MTT assay for cell viability
The 293T cells were treated with medium containing pep-
tide concentrations ranging from 0 µM to 400 µM for 6
hours at 37°C. MTT (Sigma Chemical Co, St. Louis, MO)
was added to the wells at a concentration of 50 µg/ml at
37°C for 3 hours. Subsequently, the medium was aspi-
rated, and the insoluble formazan crystals were dissolved
in a solution of 10% SDS. Absorbance readings were taken
at λ = 570 nm with background subtracted at λ = 630 nm
[28].
TAT dependent LTR-luciferase assay
To investigate if TAT dependent LTR-luciferase expression
can be inhibited by co-delivering Tat-P, 293T cells were
cotransfected with HIV LTR driven luciferase cDNA plas-
mid (pLTR-luc) and CMV driven full length TAT cDNA
plasmid (pCMV-TAT) using a calcium phosphate precipi-
tation method. Both plasmids are kindly provided by Dr.
P. Gupta of the University of Pittsburgh, School of Public
Health. At 6 hours following transfection, Tat-P and Con-
P1 peptides (200 µM, 100 µM, 50 µM) were added to the
cotransfected 293T cells, and the conditioned media were
exchanged with fresh media containing same amounts of
peptides after 12 hours. The cells were harvested 6 hours
later and processed by luciferase assay (Promega, Madison
WI) and the level of luciferase activity was determined at
24 hours using an illuminometer (AutoLumat LB 953,
EG&G berthold). The data collected were expressed as
mean ± SE, and the luciferase inhibition rate was calcu-
lated by a formula: Inhibition rate = (1 - LuminescentRetrovirology 2005, 2:71 http://www.retrovirology.com/content/2/1/71
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Units of Tat-P Treated/Luminescent Units of a Control) ×
100%.
RNA-binding assay
RNA Binding assays were performed according to a previ-
ous report [29]. Briefly, peptides and RNA were incubated
together for 15 minutes on ice in 10 µl of a binding reac-
tion mixture containing 10 mM hepes/KOH (pH 7.5),
100 mM KCl, 1 mM MgCl2, 0.5 mM EDTA, 1 mM dithio-
threitol. To determine relative binding affinities, 0.25
nmol of TAR-RNA were titrated with serial dilutions of
Tat-P, Con-P1 and Con-P2 (Peptide/RNA molar ratios are
0, 0.25, 0.5, 0.75, and 1). Free RNAs and peptide-RNA
complexes were resolved by electrophoresis at 25°C in
15% polyacrylamide gels with 1xTBE (90 mM Tris/45 mM
boric acid/1 mM EDTA) and imaged by fluorescent based
Electrophoretic Mobility Shift Assay (EMSA) kit (Molecu-
lar Probes, Eugene, OR).
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